Clinical Pharmacology of Teicoplanin in Neonates: Effects and Pharmacokinetics

نویسنده

چکیده مقاله:

Teicoplanin is a glycoside antibiotic which consists of five closely related glycopeptide antibiotics with similar antibacterial properties to vancomycin that were first isolated in 1976. Teicoplanin is active against many gram-positive anaerobe microorganisms and is particularly potent against clostridium species. It is also active against most Listeria, enterococci and staphylococci including methicillin-resistant strains. Nonviridans and viridans streptococci, Streptococcus pneumoniae, and enterococci are inhibited by teicoplanin. Teicoplanin has been used to treat a wide variety of infections, including osteomyelitis and endocarditis caused by methicillin-resistant and methicillin-susceptible staphylococci, streptococci, and enterococci. Teicoplanin has a spectrum of antimicrobial action similar to vancomycin, but teicoplanin has some advantages in that it only needs to be given once a day, does not need to be given as slowly as vancomycin and can be given by intramuscular injection. Teicoplanin cannot be given by mouth. Teicoplanin is excreted unchanged in the urine. The half-life of teicoplanin is 100 hours in adults and 21/2 days in children. Teicoplanin has a large distribution volume and long half-life and a loading dose is recommended. In infants, the loading dose of teicoplanin is 16 mg/kg administered intravenously followed by 8 mg/kg once daily. The target trough concentration of teicoplanin ranges from 15 to 30 µg/ml. The incidence of hepatic dysfunction, renal impairment and thrombocytopenia is 14.8%, 20%, and 14%, respectively, when the serum teicoplanin concentrations range from < 20 µg/ml and ≥ 20 µg/ml. The aim of this study is to review the effects and the pharmacokinetics of teicoplanin in neonates.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

clinical pharmacology of teicoplanin in neonates: effects and pharmacokinetics

teicoplanin is a glycoside antibiotic which consists of five closely related glycopeptide antibiotics with similar antibacterial properties to vancomycin that were first isolated in 1976. teicoplanin is active against many gram-positive anaerobe microorganisms and is particularly potent against clostridium species. it is also active against most listeria, enterococci and staphylococci including...

متن کامل

Clinical Pharmacology of Ceftazidime in Neonates: Effects and Pharmacokinetics

Ceftazidime is a valuable third-generation bactericidal cephalosporin. Ceftazidime inhibits the biosynthesis of bacterial cell peptidoglycan, causing inhibition of bacterial growth or cell lyses and death. Common nosocomial gram-negative organisms susceptible to ceftazidime include Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria, Moraxella catarrhalis, Proteus mirabil...

متن کامل

Clinical Pharmacology of Ciprofloxacin in Neonates: Effects and Pharmacokinetics

Ciprofloxacin is the most commonly used fluoroquinolone. Ciprofloxacin is prescribed for 1 in 44 Americans. Ciprofloxacin is a broad-spectrum bactericidal antibiotic, effective against both gram-positive and gram-negative bacteria, being especially active against the Enterobacteriacae, including many microorganisms resistant to penicillins, cephalosporins and aminoglycosides, and also is effect...

متن کامل

Clinical Pharmacology of Fluconazole in Neonates: Effects and Pharmacokinetics

Fluconazole is commonly used both to prevent and to treat invasive neonatal Candida albicans infection. This drug is a potent, selective, triazole inhibitor of the fungal enzymes involved in ergosterol synthesis. It is largely excreted unchanged in the urine. In infants with a birth weight

متن کامل

Clinical Pharmacology of Meropenem in Neonates: Effects and Pharmacokinetics

     Meropenem, a carbapenem antibiotic, has a broad-spectrum activity and is active against Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influencae, Moraxella catarrhalis, gram-negative enteric bacilli as Escherichia coli, Klebsiella, Enterobacter, Serratia and Pseudomonas aeruginosa. Meropenem has excellent penetration in body tissues and in cerebrospinal fluid (in the presenc...

متن کامل

clinical pharmacology of meropenem in neonates: effects and pharmacokinetics

meropenem, a carbapenem antibiotic, has a broad-spectrum activity and is active against staphylococcus aureus, streptococcus pneumoniae, haemophilus influencae, moraxella catarrhalis, gram-negative enteric bacilli as escherichia coli, klebsiella, enterobacter, serratia and pseudomonas aeruginosa. meropenem has excellent penetration in body tissues and in cerebrospinal fluid (in the presence of ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


عنوان ژورنال

دوره 4  شماره 10

صفحات  3669- 3684

تاریخ انتشار 2016-10-01

با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023